Problem

Life-sciences companies must manage increasingly complex regulatory requirements, large and growing volumes of adverse-event reports, and fragmented workflows across drug development, safety, regulatory, quality, and medical affairs. The pain is operational as well as economic: manual review and case processing consume specialist labor, slow safety decisions and regulatory submissions, increase compliance risk, and raise the cost of bringing products to market. The clearest “killer” use case is pharmacovigilance—capturing adverse events, processing safety cases, producing reports, and identifying signals quickly enough to protect patients and maintain a drug’s benefit-risk profile.

Product / Service

ArisGlobal sells LifeSphere, a cloud-native, integrated life-sciences software suite. Its Safety products provide a unified SaaS environment for pharmacovigilance operations, while the broader platform supports regulatory submissions, clinical data, quality, and related workflows. Automation spans intake, case management, literature assessment, reporting, analytics, and signal management; AI capabilities, including the NavaX cognitive-computing and generative-AI technology, are designed to reduce manual processing and enable more touchless safety operations. The delivery model is enterprise cloud software, with centralized updates intended to support global standardization, scalability, and ongoing regulatory compliance.

Market

ArisGlobal competes in life-sciences R&D and regulatory technology, particularly pharmacovigilance, drug-safety, regulatory-affairs, quality, and clinical-research software. Its competitive set includes Oracle Argus Safety, Veeva Vault Safety, Ennov PV Works, IQVIA, MasterControl, and other specialized regulatory and safety platforms. The company is a scaled commercial vendor rather than a pre-revenue startup: a July 2026 transaction announcement said it served more than 200 enterprise customers, including half of the world’s top 50 biopharma companies, processed more than 12 million safety cases annually, and was expected to generate approximately $175 million of 2026 revenue. The same announcement said Nordic Capital had agreed to sell the company to Dassault Systèmes, subject to the transaction’s completion.